Cara Therapeutics and Vifor Pharma announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus
March 08, 2021 01:00 ET
|
Cara Therapeutics, Inc.
FDA has set Prescription Drug User Fee Act (PDUFA) target action date of August 23, 2021If approved, KORSUVA™ injection would be first therapy for treatment of pruritus in hemodialysis patients ...
Cara Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
February 25, 2021 16:01 ET
|
Cara Therapeutics, Inc.
– U.S. FDA Accepts NDA Filing for KORSUVA™ Injection in CKD-aP – – Conference call today at 4:30 p.m. ET – STAMFORD, Conn., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:...
Cara Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
February 18, 2021 16:01 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Initiates Phase 2 Trial of Oral KORSUVA™ for the Treatment of Pruritus in Patients with Notalgia Paresthetica
January 11, 2021 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 06, 2021 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA™ Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus
December 28, 2020 07:00 ET
|
Cara Therapeutics, Inc.
First NDA submission for Company’s lead program, KORSUVA™ Injection –NDA submission includes request for Priority Review under Breakthrough Therapy Designation for KORSUVA Injection – STAMFORD,...
Cara Therapeutics Completes Full Enrollment in KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus
December 02, 2020 07:00 ET
|
Cara Therapeutics, Inc.
- Topline data expected in first half of 2021 - STAMFORD, Conn., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and...
Cara Therapeutics to Present at Multiple Upcoming Investor Conferences
November 11, 2020 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Reports Third Quarter 2020 Financial Results
November 09, 2020 16:01 ET
|
Cara Therapeutics, Inc.
– Conference call today at 4:30 p.m. ET – STAMFORD, Conn., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and...
Cara Therapeutics to Announce Third Quarter 2020 Financial Results on November 9, 2020
November 02, 2020 16:01 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...